Comment prendre rendez-vous avec Dr Jerome Avouac ?

Par téléphone au 01 58 41 41 41 (numéro publié à l'Annuaire Santé). Un lien de recherche Doctolib est proposé sur cette page : si le praticien y est inscrit, son profil figure normalement parmi les résultats.

D'où viennent les informations de cette page ?

Identité, diplômes et lieux d'exercice : Annuaire Santé (ANS, licence ouverte). Conventionnement et carte Vitale : Assurance Maladie. Publications : bases scientifiques publiques (PubMed, HAL, OpenAlex), affichées seulement si le nom du praticien figure parmi les auteurs. Le praticien peut corriger sa fiche ou en demander le retrait à tout moment ; en cas d'homonymie, signalez-le.

Dr Jerome AvouacRhumatologue à Paris 14e

Q: Où consulte Dr Jerome Avouac ?

Dr Jerome Avouac consulte à GHU APHP CUP SITE COCHIN PORT ROYAL, 27 Rue DU FAUBOURG SAINT JACQUES, 75679 Paris 14e Arrondissement. Adresses issues de l'Annuaire Santé (ANS).

Praticien hospitalier

Appeler· 01 58 41 41 41 Rechercher sur Doctolib

Photo : Stéphane Touraine, CC BY-SA 3.0, Wikimedia Commons

Dans les médias

COFER

Vous êtes Dr Jerome Avouac ? Présentation, expertises, actes, site du cabinet : faites de cette fiche la page de votre cabinet.

Configurer votre fiche gratuitement →

Dr Jerome Avouac est rhumatologue à Paris 14e (75679). Il consulte à GHU APHP CUP SITE COCHIN PORT ROYAL, 27 Rue DU FAUBOURG SAINT JACQUES, 75679 Paris 14e Arrondissement.

Enregistrer le contact

publications: 50publications
citations: 18 101citations
thèses dirigées: 3thèses dirigées
vidéo: 1vidéo

Consulter

Lieu de consultation

GHU APHP CUP SITE COCHIN PORT ROYAL

Dr Jerome Avouac, c'est vous ?

Faites de cette fiche la page de votre cabinet.

Votre présentationQuelques lignes sur votre pratique, affichées en tête de page.
Vos domaines d'expertiseLes pathologies que vous suivez, à la place des domaines déduits.
Vos actesÉchographie, infiltrations, viscosupplémentation, PRP, téléexpertise.
Vos liensSite du cabinet, LinkedIn, secteur de conventionnement corrigé.

Configurer votre fiche gratuitementGratuit · réservé au praticien

Polyarthrite rhumatoïde · 22

2026Rheumatology and therapyPubMed

Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies

2026Joint bone spinePubMed

Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice

2026Joint bone spinePubMed

Evolution of patients with active rheumatoid arthritis: Analysis of disease activity trajectories in a tertiary-care rheumatology department

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

2026Clinical rheumatologyPubMed

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study

2026Annales de cardiologie et d'angeiologiePubMed

[Correlation between carotid atheroma and DAS28 gamma GT score in rheumatoid arthritis in an African black population]

2026Rheumatology and therapyPubMed

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study

2026RMD openPubMed

Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

2026Joint bone spinePubMed

Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry

2026Joint bone spinePubMed

Baseline characteristics of the TRANSLATE2 cohort: A prospective study on rheumatoid arthritis-associated interstitial lung disease

2026Joint bone spinePubMed

Teleconsultation for rheumatoid arthritis: A selective therapeutic tool in routine care

2025The European respiratory journalPubMed

Short telomere length is associated with accelerated lung disease progression in rheumatoid arthritis-associated interstitial lung disease

2025Seminars in arthritis and rheumatismPubMed

Response to the letter to the editor entitled "Is there room for precocious prevention in rheumatoid arthritis precision medicine?"

2025Seminars in arthritis and rheumatismPubMed

Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges

2025Clinical and experimental rheumatologyPubMed

Risk factors associated with venous thromboembolism in rheumatoid arthritis in clinical practice

2025BMJ openPubMed

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

2025Arthritis research & therapyPubMed

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

2025The Journal of rheumatologyPubMed

Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study

2025Scientific reportsPubMed

Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis

2025RMD openPubMed

Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study

2024Seminars in arthritis and rheumatismPubMed

Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis

2024Joint bone spinePubMed

2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis

JAK inhibiteurs · 11

2026Rheumatology and therapyPubMed

2026Joint bone spinePubMed

Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

2026Clinical rheumatologyPubMed

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study

Sclérodermie · 8

2026Journal of autoimmunityPubMed

High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study

2026Annals of the rheumatic diseasesPubMed

High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis

2026RMD openPubMed

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study

2026Annals of the rheumatic diseasesPubMed

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series

Transversal · 8

2026Annals of the rheumatic diseasesPubMed

Immune reset after deep B-lineage depletion: remission is not reprogramming

2026Joint bone spinePubMed

Adult-onset refractory inflammatory arthritis associated with somatic mosaicism of a truncating COPA mutation

2026Arthritis & rheumatology (Hoboken, N.J.)PubMed

Mucosal-Associated Invariant T Cells in Rheumatic Diseases

2025RMD openPubMed

Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms

Revue générale · 3

2026Nature reviews. Drug discoveryPubMed

Next-generation immune cell engagers for B cell depletion in autoimmune diseases

2026Nature reviews. Drug discoveryPubMed

Roads and detours for CAR T cell therapy in autoimmune diseases

2025Rheumatology and therapyPubMed

The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations

Biothérapies non-anti-TNF · 2

2026RMD openPubMed

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study

2025BMJ openPubMed

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

Recommandations · 2

2025Joint bone spinePubMed

French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases

2025Rheumatology and therapyPubMed

The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations

Anti-TNF · 1

2026Joint bone spinePubMed

Clinical and pharmacological outcomes after switching from intravenous to subcutaneous infliximab in chronic inflammatory rheumatic diseases

Arthrite juvénile · 1

2025Joint bone spinePubMed

Intestinal barrier biomarkers in adult patients with juvenile idiopathic arthritis in transition

Connectivite mixte · 1

2025Clinical and experimental rheumatologyPubMed

Nailfold videocapillaroscopy findings and associations with organ involvement in mixed connective tissue disease

csDMARDs · 1

2024Rheumatology and therapyPubMed

Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary

Échographie · 1

2026Seminars in arthritis and rheumatismPubMed

Hand function impairment in Systemic Sclerosis: determinants through investigations of clinical, radiographic and ultrasonographic features

Épidémiologie & registres · 1

2025The Lancet. RheumatologyPubMed

Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study

Fibromyalgie · 1

2026La Revue de medecine internePubMed

[Care pathway to diagnosis in fibromyalgia and inflammatory rheumatic diseases: A patient-centered approach using a comparative mixed-methods study]

Pharmacovigilance · 1

2025Rheumatology and therapyPubMed

The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations

Polymyalgia rheumatica · 1

2026Rheumatology (Oxford, England)PubMed

18F-fluorodeoxyglucose PET/CT uptake characteristics in immune checkpoint inhibitor-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumatica

Risque cardio-vasculaire · 1

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

Dr Jerome AvouacRhumatologue à Paris 14e

Lieu de consultation

Préparer votre rendez-vous

Conventionnement et remboursement

Expertise et points clés

Parcours et diplômes (9)

Travaux scientifiques (62)

Vidéos et presse (1)

Questions fréquentes sur Dr Jerome Avouac

Où consulte Dr Jerome Avouac ?

Comment prendre rendez-vous avec Dr Jerome Avouac ?

D'où viennent les informations de cette page ?

Rhumatologues à Paris 14e et alentours